# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and maintains $10 price target.
Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0....
HC Wainwright & Co. analyst Arthur He initiates coverage on Prime Medicine (NASDAQ:PRME) with a Buy rating and announces...
Citigroup analyst Samantha Semenkow upgrades Prime Medicine (NASDAQ:PRME) from Neutral to Buy and announces $10 price target.
JP Morgan analyst Eric Joseph maintains Prime Medicine (NASDAQ:PRME) with a Overweight and lowers the price target from $16 ...
Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.47...
Findings demonstrate ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored ...
Jefferies analyst Maury Raycroft assumes Prime Medicine (NASDAQ:PRME) with a Buy rating and lowers Price Target of $15.